Ethmozine

(moricizine)

Phase 3Small molecule

UUniversity of Hertfordshire

Ethmozine is one of 55 small molecule programs targeting Cardiac Arrhythmia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrhythmiaActive, not recruiting

Atrial FibrillationActive, not recruiting

Cardiac ArrhythmiaPhase 3

Active, not recruiting

Atrial FibrillationPhase 3

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Ethmozine

UUniversity of Hertfordshire

Phase 3

1 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Calan

4 5

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 6

Brukinsa

BBeOne Medicines

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Imbruvica

PPharmacyclics LLC.

Preclinical

1 9

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Versed

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiac Arrhythmia2 trials

Cardiac Arrhythmia Suppression Trial (CAST)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000526

Cardiac Arrhythmia Pilot Study (CAPS)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00000504

Atrial Fibrillation1 trial

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000556

Regulatory

FDA Approval Timeline[4]

Jun 19, 1990

ETHMOZINE

NDA NDA019753

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for moricizine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — moricizine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for moricizine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019753). U.S. Food & Drug Administration.
[5]
SEC EDGAR — University of Hertfordshire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Hertfordshire

Ethmozine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiac Arrhythmia2 trials

Atrial Fibrillation1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News